top of page

Outsourced trials - outsized problems

Updated: Oct 17, 2018

A good summary of the main issue: “The pharmaceutical industry needs to engage properly with the regulators and stop interpreting what they believe is expected of them”. “Those of us who still run academic studies within the same regulatory frameworks know full well that most of what is being asked for in the name of quality and safety is not required.”

Read the full article below:


bottom of page